Loading
Total declarations
Companies
▲ Purchases (40 ops.)
▼ Sales (0 ops.)
Latest filing published 23 Dec 2025 for IN8BIO, INC., €85k.
Filing timeline
BuySalePeter C. Brandt
Insider track record
Disclosed buys
40
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Peter C. Brandt: trading record in brief
This profile gathers the share dealings of Peter C. Brandt across 5 companies, led by Opus Genetics, Inc., Noven Pharmaceuticals Inc and Epocrates Inc. In total, 55 filings cover trades dated from 29 April 2008 to 22 December 2025.
No open-market sale appears; the market trades are 40 purchases worth €969k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 8 share grants and 2 option exercises.
In size, the median ticket on the buying side is €4,471.
On 23 December 2025 came the latest disclosure, a share grant for €85k in In8bio, Inc. The last insider purchase was made public on 18 August 2022, 1,528 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Peter C. Brandt
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
72,464 shares@ US$1.38Common StockSEC:0001434099-25-000004:0
81,967 shares@ US$0.18446.4% of flowCommon StockSEC:0001415889-25-012286:0
253,164 sharesCommon StockSEC:0001415889-24-024867:0
81,967 sharesCommon StockSEC:0001209191-23-058713:0
105,263 shares@ US$1.9093.6% of flowCommon StockSEC:0001209191-22-046598:0
Canonical exit: 14 Nov 2022 (T+90)
5 of 5 declarations
